Scancell Holdings is set to transfer its primary listing to the Nasdaq stock exchange, a move that underscores the continuing erosion of the London Stock Exchange's Aim market.
The biotechnology company's shares fell 27% this week, a sharp decline that market observers note obscures the strategic shift toward a US listing.
The departure of Scancell contributes to a broader trend of shrinking headcount on the UK's junior market, which has seen its number of listed companies drop to 612.
The move to Nasdaq represents a significant step for Scancell, aiming to access deeper liquidity and greater visibility among international investors.
While the recent share price volatility reflects short-term market sentiment, the long-term strategy appears focused on stabilizing the company's capital base in a more robust trading environment.
The delisting from Aim removes one of the few remaining high-profile names from the segment, further reducing the diversity of the UK's small-cap ecosystem.